Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics
Allan Lipton,Karim Fizazi,Alison Stopeck,David H. Henry,Matthew R. Smith,N. Shore,Miguel Martin,Saroj Vadhan-Raj,Janet E. Brown,Gary Richardson,Fred Saad,Denise A. Yardley,K. Zhou,Arun Balakumaran,Ada Braun +14 more
TLDR
Denosumab was superior to ZA in preventing SREs in patients with bone metastases from advanced cancer, regardless of ECOG PS, bone metastasis number, baseline visceral metastasis presence/absence, and uNTx level.About:
This article is published in European Journal of Cancer.The article was published on 2016-01-01 and is currently open access. It has received 93 citations till now. The article focuses on the topics: Denosumab & Bone metastasis.read more
Citations
More filters
Journal ArticleDOI
Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management.
TL;DR: Bone metastases negatively impact on patients’ quality of life (QoL) and survival and bone turnover modulators reduce the risk of skeletal complications and improve pain.
Journal ArticleDOI
RANK–RANKL signalling in cancer
Nathalie Renema,Benjamin Navet,Marie-Françoise Heymann,Frédéric Lézot,Dominique Heymann,Dominique Heymann +5 more
TL;DR: The aim of the present review is to provide an overview of the functional implication of the RANK/RANKL system in cancer development, and to underline the most recent clinical studies.
Journal ArticleDOI
Bone-targeted therapies in cancer-induced bone disease
TL;DR: This review will focus on the evolution of bone-targeted therapies for the treatment of cancer-induced bone disease, summarizing preclinical and clinical findings obtained with anti-resorptive and bone anabolic therapies.
Journal ArticleDOI
Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study
María Belén Zanchetta,J. Boailchuk,Fabio Massari,Fernando Silveira,Cesar E. Bogado,Jose R. Zanchetta +5 more
TL;DR: The results describe the rapid bone loss occurring after cessation of denosumab treatment and the role of transitioning to bisphosphonates in the long term.
Journal ArticleDOI
Immune system and bone microenvironment: rationale for targeted cancer therapies.
Gnoni Antonio,Brunetti Oronzo,Longo Vito,Calabrese Angela,Argentiero Antonel-la,Calbi Roberto,Solimando Antonio Giovanni,Licchetta Antonella +7 more
TL;DR: Initial data evidenced a possible anti-bone resorption effect of systemic anticancer drugs through and immunomodulation activity, i.e. new generation antiandrogens (Abiraterone) in prostate cancer and all data could open a future rationale of combined bone, immunologic and targeted therapies in cancer treatment.
References
More filters
Journal ArticleDOI
Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity
TL;DR: Improved understanding of prognostic and predictive factors may enable delivery of a more personalized treatment for the individual patient and a more cost-effective use of health care resources.
Journal ArticleDOI
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
Karim Fizazi,Michael A. Carducci,Matthew R. Smith,Ronaldo Damião,Janet E. Brown,Lawrence Karsh,Piotr Milecki,Neal D. Shore,Michael Rader,H. Wang,Qi Jiang,Sylvia Tadros,Roger Dansey,Carsten Goessl +13 more
TL;DR: Denosumab was better than zoledronic acid for prevention of skeletal-related events, and potentially represents a novel treatment option in men with bone metastases from castration-resistant prostate cancer.
Journal ArticleDOI
Skeletal complications of malignancy
TL;DR: Good prognostic factors for survival after the development of bone metastases are good histologic grade, positive estrogen receptor status, bone disease at initial presentation, a long disease free interval, and increasing age, while patients with disease that remains confined to the skeleton have a better prognosis than those with subsequent visceral involvement.
Journal ArticleDOI
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
Alison Stopeck,Allan Lipton,Jean-Jacques Body,Guenther G. Steger,Katia Tonkin,Richard De Boer,Mikhail Lichinitser,Yasuhiro Fujiwara,Denise A. Yardley,María Viniegra,Michelle Fan,Qi Jiang,Roger Dansey,Susie Jun,Ada Braun +14 more
TL;DR: With the convenience of a subcutaneous injection and no requirement for renal monitoring, denosumab represents a potential treatment option for patients with bone metastases.
Journal ArticleDOI
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
David H. Henry,Luis Costa,François Goldwasser,Vera Hirsh,Vania Hungria,Jana Prausova,Giorgio V. Scagliotti,Harm Sleeboom,Andrew Spencer,Saroj Vadhan-Raj,Roger von Moos,Wolfgang Willenbacher,Penella J. Woll,Jianming Wang,Qi Jiang,Susie Jun,Roger Dansey,Howard S. Yeh +17 more
TL;DR: Denosumab was noninferior (trending to superiority) to ZA in preventing or delaying first on-study SRE in patients with advanced cancer metastatic to bone or myeloma and represents a potential novel treatment option with the convenience of subcutaneous administration and no requirement for renal monitoring or dose adjustment.
Related Papers (5)
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Chris Parker,Sten Nilsson,Sten Nilsson,D. Heinrich,Svein Inge Helle,Joe M. O'Sullivan,Sophie D. Fosså,Ales Chodacki,Paweł Wiechno,John P Logue,Mihalj Seke,Anders Widmark,D. C. Johannessen,Peter Hoskin,David Bottomley,Nicholas D. James,Arne Solberg,Isabel Syndikus,Ján Kliment,S. Wedel,S. Boehmer,Marcos F. Dall'Oglio,Lars Franzén,Robert E. Coleman,Nicholas J. Vogelzang,C.G. O'Bryan-Tear,K. Staudacher,J. Garcia-Vargas,M. Shan,Øyvind S. Bruland,Oliver Sartor +30 more